Search Result

Isoforms Recommended:	KDM5

Results for "

KDM5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Histone Demethylase (22) Small Interfering RNA (siRNA) (4)
By Research Areas:	Cancer (21) Cardiovascular Disease (2)

Inhibitors & Agonists

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-120400

KDM5-C70 3 Publications Verification	Histone Demethylase	Cancer
KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels .

HY-100422

KDM5-IN-1

1 Publications Verification

Histone Demethylase Cancer

KDM5-IN-1 is a potent, selective and orally bioavailable KDM5 inhibitor with an IC₅₀ of 15.1 nM.

KDM5-IN-1 1 Publications Verification	Histone Demethylase	Cancer
KDM5-IN-1 is a potent, selective and orally bioavailable *KDM5* inhibitor with an IC₅₀ of 15.1 nM.

HY-119397A

KDM5-C49 hydrochloride KDOAM-20 hydrochloride	Histone Demethylase	Cancer
KDM5-C49 (KDOAM-20) hydrochloride is a potent and selective inhibitor of KDM5 demethylases, with IC₅₀s of 40 nM, 160 nM, and 100 nM for *KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM5*-C49 hydrochloride can be used for the research of cancer .

HY-100014

KDM5A-IN-1 2 Publications Verification	Histone Demethylase	Cancer
KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 45 nM, 56 nM and 55 nM for *KDM5A, KDM5B* and *KDM5C, respectively, and with an EC₅₀* value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other *KDM5B* enzymes (1A, 2B, 3B, 4C, 6A, 7B) .

HY-119397

KDM5-C49 KDOAM-20	Histone Demethylase	Cancer
KDM5-C49 (KDOAM-20) is a potent and selective inhibitor of KDM5 demethylases, with IC₅₀s of 40 nM, 160 nM, and 100 nM for *KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM5*-C49 can be used for the research of cancer .

HY-146670

KDM5B-IN-3	Histone Demethylase	Cancer
KDM5B-IN-3 (Compound 5) is a histone lysine specific demethylase 5B (KDM5B/JARID1B) inhibitor with an IC₅₀ of 9.32 μM. KDM5B-IN-3 can be used for the research of gastric cancer .

HY-149091

KDM5B-IN-4	Others	Cancer
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC₅₀ of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting *KDM5B* in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs .

HY-RS07218

KDM5A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KDM5A Human Pre-designed siRNA Set A contains three designed siRNAs for KDM5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KDM5A Human Pre-designed siRNA Set A KDM5A Human Pre-designed siRNA Set A

HY-RS07219

KDM5B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KDM5B Human Pre-designed siRNA Set A contains three designed siRNAs for KDM5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KDM5B Human Pre-designed siRNA Set A KDM5B Human Pre-designed siRNA Set A

HY-RS07220

KDM5C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KDM5C Human Pre-designed siRNA Set A contains three designed siRNAs for KDM5C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KDM5C Human Pre-designed siRNA Set A KDM5C Human Pre-designed siRNA Set A

HY-RS07221

KDM5D Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KDM5D Human Pre-designed siRNA Set A contains three designed siRNAs for KDM5D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KDM5D Human Pre-designed siRNA Set A KDM5D Human Pre-designed siRNA Set A

HY-138691

JQKD82 JADA82; PCK82	Histone Demethylase	Cancer
JQKD82 (JADA82) is a cell-permeable and selective *KDM5* inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma .

HY-138691A

JQKD82 trihydrochloride JADA82 trihydrochloride; PCK82 trihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective *KDM5* inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma .

HY-138691B

JQKD82 dihydrochloride JADA82 dihydrochloride; PCK82 dihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) dihydrochloride is a cell-permeable and selective *KDM5* inhibitor. JQKD82 dihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma .

HY-102047

KDOAM-25	Histone Demethylase	Cancer
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-102047A

KDOAM-25 trihydrochloride	Histone Demethylase	Cancer
KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-100421

CPI-455 5 Publications Verification	Histone Demethylase	Cancer
CPI-455 is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-100421A

CPI-455 hydrochloride	Histone Demethylase	Cancer
CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-102047B

KDOAM-25 citrate 3 Publications Verification	Histone Demethylase	Cancer
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-128343

KDM4-IN-2

Histone Demethylase Cancer

KDM4-IN-2 (Compound 19a) is a potent and selective KDM4/KDM5 dual inhibitor with K_is of 4 and 7 nM for KDM4A and KDM5B, respectively .

KDM4-IN-2	Histone Demethylase	Cancer
KDM4-IN-2 (Compound 19a) is a potent and selective *KDM4/KDM5* dual inhibitor with K_is of 4 and 7 nM for KDM4A and KDM5B, respectively .

HY-104048

QC6352 4 Publications Verification	Histone Demethylase	Cancer
QC6352 is an orally active *KDM4* inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits *KDM4* different isoforms with IC₅₀s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against *KDM5* with an IC₅₀ of 750 nM (KDM5B) .

HY-151483

TK-129	Histone Demethylase	Cardiovascular Disease
TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC₅₀=44 nM). TK-129 exerts cardioprotective effects by inhibiting *KDM5B* and blocking the *KDM5B*-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease .

HY-100764

YUKA1	Histone Demethylase	Cancer
YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC₅₀ of 2.66 μM, less active on KDM5C (IC₅₀, 7.12 μM), and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 increases H3K4me3 levels in human cells with anti-cancer activity .

HY-100744

AS8351 NSC51355	Histone Demethylase	Cardiovascular Disease
AS8351 (NSC51355) is a *KDM5B* inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells .

HY-123419

CPI-4203	Histone Demethylase	Cancer
CPI-4203 is a potent *KDM5A* inhibitor with an IC₅₀ of 250 nM. CPI-4203 is competitive with 2-oxoglutarate (2-OG). CPI-4203 is structurally related to CPI-455 (HY-100421) but is less potent .

HY-116761

GSK467 2 Publications Verification	Histone Demethylase	Cancer
GSK467 is a cell penetrant and selective *KDM5B* (JARID1B or PLU1) inhibitor with a K_i of 10 nM and an IC₅₀ of 26 nM. GSK467 shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members .

HY-101451

PBIT 2 Publications Verification
PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. PBIT inhibits JARID1B (KDM5B or PLU1) histone demethylase with an IC₅₀ of about 3 μM . PBIT also inhibits JARID1A and JARID1C with IC₅₀s of 6 μM and 4.9 μM, respectively .

HY-107573

KDM2/7-IN-1 1 Publications Verification	Histone Demethylase	Cancer
KDM2/7-IN-1 (TC-E 5002) is a selective histone demethylase *KDM2/7* subfamily inhibitor (IC₅₀ values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). KDM2/7-IN-1 inhibits growth of HeLa and KYSE-150 cancer cells in vitro .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.